Literature DB >> 27118262

LncRNA uc.48+ siRNA improved diabetic sympathetic neuropathy in type 2 diabetic rats mediated by P2X7 receptor in SCG.

Bing Wu1, Chunping Zhang1, Lifang Zou1, Yucheng Ma2, Kangyu Huang2, Qiulan Lv1, Xi Zhang1, Shouyu Wang1, Yun Xue1, Zhihua Yi1, Tianyu Jia1, Shanhong Zhao1, Shuangmei Liu1, Hong Xu1, Guilin Li3, Shangdong Liang4.   

Abstract

Diabetic autonomic neuropathy includes the sympathetic ganglionic dysfunction. P2X7 receptor in superior cervical ganglia (SCG) participated in the pathological changes of cardiac dysfunction. Abnormal expression of long noncoding RNAs (lncRNAs) was reported to be involved in nervous system diseases. Our preliminary results obtained from rat lncRNA array profiling revealed that the expression of the uc.48+ was significantly increased in the rat SCG in response to diabetic sympathetic pathology. In this study, we found that lncRNAuc.48+ and P2X7 receptor in the SCG were increased in type 2 diabetic rats and were associated with the cardiac dysfunction. The uc.48+ small interference RNA (siRNA) improved the cardiac autonomic dysfunction and decreased the up-regulation P2X7 and the ratio of phosphorylated extracellular regulated protein kinases1/2 (p-ERK1/2) to ERK1/2 in SCG of type 2 diabetic rats. In conclusion, lncRNA uc.48+ siRNA improved diabetic sympathetic neuropathy in type 2 diabetic rats through regulating the expression of P2X7 and ERK signaling in SCG.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Long noncoding RNA; P2X(7) receptor; Superior cervical ganglia; Type 2 diabetes

Mesh:

Substances:

Year:  2016        PMID: 27118262     DOI: 10.1016/j.autneu.2016.04.001

Source DB:  PubMed          Journal:  Auton Neurosci        ISSN: 1566-0702            Impact factor:   3.145


  13 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

2.  Involvement of P2Y12 receptor of stellate ganglion in diabetic cardiovascular autonomic neuropathy.

Authors:  Jingjing Guo; Xuan Sheng; Yu Dan; Yurong Xu; Yuanruohan Zhang; Huihong Ji; Jiayue Wang; Zixi Xu; Hongyu Che; Guodong Li; Shangdong Liang; Guilin Li
Journal:  Purinergic Signal       Date:  2018-08-06       Impact factor: 3.765

Review 3.  Interactions Among lncRNAs/circRNAs, miRNAs, and mRNAs in Neuropathic Pain.

Authors:  Ge Song; Zheng Yang; Jiabao Guo; Yili Zheng; Xuan Su; Xueqiang Wang
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

Review 4.  LncRNAs: key players and novel insights into diabetes mellitus.

Authors:  Xiaoyun He; Chunlin Ou; Yanhua Xiao; Qing Han; Hao Li; Suxian Zhou
Journal:  Oncotarget       Date:  2017-08-04

Review 5.  The Big Entity of New RNA World: Long Non-Coding RNAs in Microvascular Complications of Diabetes.

Authors:  Satish K Raut; Madhu Khullar
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-04       Impact factor: 5.555

Review 6.  The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.

Authors:  Geoffrey Burnstock; Gillian E Knight
Journal:  Purinergic Signal       Date:  2017-11-21       Impact factor: 3.765

7.  Dysregulation of lncRNAs GM5524 and GM15645 involved in high‑glucose‑induced podocyte apoptosis and autophagy in diabetic nephropathy.

Authors:  Yamin Feng; Sheng Chen; Jiarong Xu; Qun Zhu; Xiaolong Ye; Dafa Ding; Weihao Yao; Yibing Lu
Journal:  Mol Med Rep       Date:  2018-08-21       Impact factor: 2.952

Review 8.  Functional roles of lncRNAs and its potential mechanisms in neuropathic pain.

Authors:  Simin Tang; Jun Zhou; Huan Jing; Meijuan Liao; Sen Lin; Zhenxing Huang; Teng Huang; Jiying Zhong
Journal:  Clin Epigenetics       Date:  2019-05-15       Impact factor: 6.551

Review 9.  Advances with Long Non-Coding RNAs in Diabetic Peripheral Neuropathy.

Authors:  Men Wu; Yonghao Feng; Xiaohong Shi
Journal:  Diabetes Metab Syndr Obes       Date:  2020-04-30       Impact factor: 3.168

Review 10.  Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets.

Authors:  B Alipoor; S Nikouei; F Rezaeinejad; S-N Malakooti-Dehkordi; Z Sabati; H Ghasemi
Journal:  J Endocrinol Invest       Date:  2021-04-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.